Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 59, Issue 7, 2012, Pages 1284-1289

  Appel, Burton E ^a   Chen, Lu ^b   Buxton, Allen ^b   Wolden, Suzanne L ^c   Hodgson, David C ^d   Nachman, James B ^e  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Children's Oncology Group; Hodgkin lymphoma; Lymphocyte predominant

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; YOUNG ADULT;

EID: 84867364054     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24258     Document Type: Article

References (51)

1. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337: 453-458.
2. Ohno T, Stribley JA, Wu JA, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337: 459-465.
3. Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 1997; 94: 9337-9342.
4. Vasef MA, Alsabeh R, Medeiros LJ, et al. Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease. Am J Clin Pathol 1997; 108: 54-59.
5. Anagnostopoulos I, Hansmann M, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000; 96: 1889-1899.
6. Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15: 3060-3066.
7. Nogová L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26: 434-439.
8. Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol 2007; 17: 184-189.
9. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2009; 28: 136-141.
10. Karayalcin G, Behm FG, Gieser PW, et al. Lymphocyte-predominant Hodgkin disease: Clinico-pathologic features and results of treatment-the Pediatric Oncology Group experience. Med Pediatr Oncol 1997; 29: 519-525.
11. Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte-predominant Hodgkin lymphoma--A Children's Cancer and Leukaemia Group report. Br J Haematol 2007; 138: 761-768.
12. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25: 332-337.
13. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771.
14. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063-1081.
15. Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin's disease: Long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997; 26: 359-368.
16. Sandoval C, Venkateswaran L, Billups C, et al. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002; 24: 269-273.
17. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25: 684-687.
18. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: Therapeutic abstention after initial lymph node resection--A study of the French Society of Pediatric Onocolgy. J Clin Oncol 2003; 21: 2948-2952.
19. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma--Experience from the European Network Group on Pediatric Hodgkin Lymphoma. Cancer 2007; 110: 179-185.
20. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: A long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116: 631-639.
21. Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010; 21: 2061-2068.
22. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1999; 17: 776-783.
23. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer 2005; 104: 1221-1229.
24. Krasin MJ, Constine LS, Friedman D, et al. Radiation-related treatment effects across the age spectrum: Differences and similarities or what the old and young can learn from each other. Semin Radiat Oncol 2010; 20: 21-29.
25. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148.
26. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25: 43-49.
27. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-1315.
28. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751.
29. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998; 16: 536-544.
30. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 2000; 18: 498-509.
31. Ng AK, Bernardo MVP, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 2002; 100: 1989-1996.
32. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386-4394.
33. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25: 1489-1497.
34. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: Associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008; 72: 24-33.
35. O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28: 1232-1239.
36. Hobbie WL, Ginsberg JP, Ogle SK, et al. Fertility in males treated for Hodgkin's disease with COPP/ABV hybrid. Pediatr Blood Cancer 44: 193-196.
37. Sieniawksi M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008; 19: 1795-1801.
38. Green DM, Sklar CA, Boice JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2374-2381.
39. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-533.
40. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002; 8: 377-384.
41. Van Grotel M, Lam KH, De Man R, et al. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma 2006; 47: 1504-1510.
42. Canellos GP. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol 2010; 28: e8.
43. Savage K, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011; 118: 4585-4590.
44. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early-stage nodular lymphocyte predominant Hodgkin's lymphoma-an Anglo-French collaborative report. Eur J Cancer 2011; DOI: 10.1016/j.ejca.2011.10.018.
45. Hansmann ML, Zwingers T, Boske A, et al. Clinical features of nodular paraganglioma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984; 108: 321-330.
46. Schellong G, Potter R, Branswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian Multicenter Trial DAL-HD-90. J Clin Oncol 1999; 17: 3736-3744.
47. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 2011; 118: 4363-4365.
48. Saini KS, Azim HA, Cocorocchio E, et al. Rituximab in Hodgkin lymphoma: Is the target always a hit? Cancer Treat Rev 2011; 37: 385-390.
49. Miettinen M, Franssila KO, Saxén E. Hodgkin's disease, lymphocytic predominance nodular--increased risk for subsequent non-Hodgkin's lymphoma. Cancer 1983; 51: 2293-2300.
50. Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2004; 45: 1551-1557.
51. Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28: 793-799.